Why 80% of Americans will LIKELY be on a GLP-1 within 5-10 years 👇🏻👇🏻👇🏻 Get ready to have your mind blown 🤯 The SELECT trial showed a 20% reduction in heart attacks, strokes, and cardiovascular death in people who didn't even have diabetes. That alone would justify mass adoption. Heart disease is still the #1 killer in this country. Then a JAMA Network Open study of over 840,000 breast cancer patients found GLP-1 use was linked to improved survival and reduced recurrence, especially for those with obesity or type 2 diabetes — enough to warrant further research. A newer study presented at ASCO 2026 found GLP-1 use linked to roughly 30% lower breast cancer risk across 111,000 women. And in women already diagnosed, those on a GLP-1 were reportedly far less likely to progress to stage 4. Why? Inflammation. GLP-1s lower systemic inflammation independent of weight loss — CRP drops, inflammatory cytokines drop. Chronic inflammation is the root driver of nearly every age-related disease, so this one lever touches almost everything downstream. The STEP-HFpEF trial showed major improvement in heart failure symptoms. The FLOW trial showed a 24% reduction in kidney disease progression. Heart, kidneys, vessels — all protected. The SURMOUNT-OSA trial showed tirzepatide cut sleep apnea events by up to 63%. No CPAP machine touches that. And better sleep cascades into better metabolism, mood, and cognition. Knee osteoarthritis pain dropped dramatically in the STEP 9 trial — far beyond what weight loss alone would predict. People are walking again. That anti-inflammatory effect appears to act directly on joint tissue. There are even early signals in autoimmune conditions. Patients with psoriasis, rheumatoid arthritis, lupus, and IBD are reporting flare reduction, likely through gut-immune axis modulation. And there's emerging data on addiction — alcohol, nicotine, gambling, opioids. GLP-1s appear to dampen the brain's reward loop. If even half of this pans out, it reshapes public health on a scale we haven't seen in a century.